SCHEMBL6315950

SCHEMBL6315950

Nc1onc(-c2ccccn2)c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
GABRA5 P31644 2/20 0.43
KDM6B O15054 1/20 0.43
KDM4A O75164 1/20 0.43
KDM5C P41229 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
KDM3A Q9Y4C1 1/20 0.43
TDO2 P48775 1/20 0.43
PIN1 Q13526 1/20 0.40
GRM5 P41594 1/20 0.40
RET P07949 1/20 0.40
LMNA P02545 3/20 0.40
P4HTM Q9NXG6 2/20 0.40
NAPRT Q6XQN6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318141 0.88 RET (0.47) KDM4EGABRA5TDO2GRM5RET
SCHEMBL6317780 0.84 MAPT (0.49) GABRA5TDO2LMNATP53PKM
SCHEMBL6316151 0.84 CA1 (0.56) LMNACA1CA2CA4CA7
SCHEMBL409574 0.83 PTPN1 (0.46) KDM4EGABRA5KDM6BKDM4AKDM5C
SCHEMBL6315512 0.83 LMNA (0.56) KDM4EGABRA5TDO2RETLMNA
SCHEMBL30684510 0.82 GABRA5 (0.54) KDM4EGABRA5KDM6BKDM4AKDM5C
SCHEMBL12543755 0.82 GABRA5 (0.54) KDM4EGABRA5KDM6BKDM4AKDM5C
SCHEMBL6315249 0.81 ALDH1A1 (0.47) GABRA5LMNAL3MBTL1CA1CA2
SCHEMBL6319053 0.81 HPGDS (0.54) KDM4ELMNASMN1; SMN2NPC1CYP1A2
SCHEMBL27837002 0.78 ESR1 (0.41) KDM4EGABRA5KDM6BKDM4AKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KDM4E 1382/4885GABRA5 742/4885KDM6B 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.